| PG |
Report |
Q4 FY2026 Core EPS |
BEAT |
pred ~$1.43 vs. cons $1.407 |
MEDIUM |
| PG |
Report |
Q4 FY2026 Organic Sales Growth |
MISS |
pred ~+1.0% vs. cons +1.62% |
MEDIUM |
| PG |
Report |
FY2027 Core EPS (first guidance) |
MISS |
pred ~$6.90 mid vs. cons $7.00 |
MEDIUM |
| PG |
Guide |
FY2027 Core EPS (FY2027) |
LOWER |
guide ~$6.80-$7.00 mid $6.90 vs. cons $7.00 |
MEDIUM |
| PG |
Guide |
FY2027 Organic Sales Growth (FY2027) |
BETTER |
guide ~+2%-+4% mid ~+3% vs. cons +2.5% |
MEDIUM |
| PG |
Guide |
FY2026 Full-Year Core EPS (FY2026) |
UNCHANGED |
narrow to $6.83-$6.90, in-line with cons $6.88 |
HIGH |
| PG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| PG |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side FY2027 EPS cuts ($7.00 to ~$6.90) extend the move; no catalyst to reverse in 5 days |
MEDIUM |